On October 2, 2019, the Federal Circuit will hear oral arguments in 23andMe and Ancestry.com, a case that questions whether a patent involving hybrid technologies is patentable under Section 101. Law.com reached to Finnegan partner Aaron Capron for his thoughts on the case.
Aaron is watching the case closely, as it involves both biotechnology and big data. The question is whether the Federal Circuit will analyze the patents under the law of nature (used for patents in the biotech field) or if the court will apply the abstract idea test (reserved for software patents). Because the patent in question straddles both industries, Aaron wonders if a separate test will be created for this hybrid space.
Media Mention
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.